A5055517858- Venous Thromboembolism Diagnosis and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Blood properties and coagulation
- Atrial Fibrillation Management and Outcomes
- Blood Coagulation and Thrombosis Mechanisms
- Peripheral Artery Disease Management
- Lipoproteins and Cardiovascular Health
- Liver Disease Diagnosis and Treatment
- Diagnosis and Treatment of Venous Diseases
- Acute Ischemic Stroke Management
- Hemophilia Treatment and Research
- Neurological Disorders and Treatments
- Liver Disease and Transplantation
- Platelet Disorders and Treatments
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Organ Transplantation Techniques and Outcomes
- Cerebrovascular and Carotid Artery Diseases
- Cardiovascular Health and Disease Prevention
- Cancer Treatment and Pharmacology
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Inflammatory mediators and NSAID effects
- Acute Myocardial Infarction Research
- Diet and metabolism studies
- Folate and B Vitamins Research
- Proteoglycans and glycosaminoglycans research
University of Bologna
2011-2022
Policlinico S.Orsola-Malpighi
1997-2016
University of Ferrara
2003
Policlinico Umberto I
1997
Azienda Ospedaliera Ospedale Maggiore
1997
University of Milan
1989-1993
Dialyse Centrum Groningen
1992
Luigi Sacco Hospital
1992
Medica (Italy)
1962-1987
St George's Hospital
1985
Summary In some patients with previous venous thromboembolism (VTE) D-dimer levels (D-Dimer) tend to increase after oral anticoagulant therapy (OAT) is stopped. The aim of our study was evaluate the predictive value D-Dimer for risk VTE recurrence OAT withdrawal. After a first episode deep vein thrombosis (DVT) lower limbs and/or pulmonary embolism (PE), 396 (median age 67 years, 198 males) were followed from day discontinuation 21 months. measured on withdrawal (T1), 3-4 weeks (T2) and 3...
Background— We have shown that normal D-dimer levels obtained after the discontinuation of oral anticoagulant treatment (OAT) has a high negative predictive value for recurrent venous thromboembolism (VTE). The aim present study was to assess VTE in subjects with previous unprovoked event who are either carriers inherited thrombophilia or not. Methods and Results— prospectively evaluated 599 patients (301 males) episode. They were repeatedly examined OAT withdrawal screened thrombophilic...
Background and Purpose The results of a large prospective randomized trial have shown the efficacy oral anticoagulation in secondary prevention major vascular events patients with nonrheumatic atrial fibrillation (NRAF); less well established is role antiplatelet agents. present study compared effects indobufen, reversible inhibitor platelet cyclooxygenase, those warfarin this setting. Methods A total 916 NRAF recent (≤15 days) cerebral ischemic episode were admitted to multicenter, study,...
Patients with diabetes are at excessive risk of mortality and cardiovascular morbidity. Previous studies suggest that aspirin may be less effective in diabetic patients. In this multi-centre, randomized, double blind trial picotamide, a dual inhibitor thromboxane A2 synthase receptor, was compared for the prevention major events diabetics peripheral arterial disease (PAD).A total 1209 adults aged 40-75 years type 2 PAD were randomized to receive picotamide (600 mg bid) or (320 od) 24 months....
The occurrence of a "rebound hypercoagulable state" in patients after dicontinuation oral anticoagulants is still matter debate and no definite recommendation can be made on the best procedure for anticoagulant withdrawal. present study investigated changes levels markers activated blood coagulation 32 (pts) whom warfarin treatment (for venous thromboembolic disease) was randomly withdrawn abruptly (n = 17, group A) or gradually 15, B: 2/3 initial dose 1st week, 1/3 2nd weeks nothing from...
The overflow of studies in the recent literature on COVID-19 often gives provisional or contradictory results and therefore deserves pauses reflection reconsideration. In fact, knowledges pathophysiology this new disease are still development hence originate discussions interpretations. Regarding role blood coagulation fibrinolysis, these mechanisms should be considered as crucial especially severe cases. It is proposed to consider two distinct phenotypes thrombotic manifestations: current...
Sulodexide, a highly purified glycosaminoglycan, was investigated for treatment of venous leg ulcers. Patients (n = 235) undergoing local including wound care and compression bandaging, were randomised to receive either sulodexide or matching placebo three months. Primary study endpoint complete ulcer healing after 2 months; secondary endpoints at 3 months the time-course changes areas. The proportion patients with higher (p 0.018) "number needed treat" obtain one additional patient healed 7...
Summary The paper reports on rate and type of thrombotic events occurring during the observational, prospective, inception-cohort, multicenter ISCOAT study. 2,745 unselected, daily practice patients, consecutively referring to 34 Italian anticoagulation clinics monitor oral anticoagulant treatment, were included in study from beginning their first course. During a total follow-up 2,011 patient-years treatment 70 (3.5 per 100 patient years) recorded 67 patients: 20 fatal (1%), 39 major (1.9%)...
SummaryThromboplastic and fibrinolytic activity was estimated in layers of large human vessels. Arterial intima has higher thromboplastic lower plasminogen activator concentrations (usually zero) than the systemic veins (vena cava inf.). In all vessels adventitia high activity.
Aims Patients with peripheral arterial obstructive disease require treatment to prevent major cardiovascular events and relieve intermittent claudication. The walking performance of patients was used evaluate the usefulness sulodexide, a glycosaminoglycan containing fast moving heparin dermatan sulphate.
Patients undergoing surgery for cancer are at high risk venous thromboembolism (VTE). Agents that selectively inhibit thrombin, such as dermatan sulphate, have potential a favourable benefit-risk ratio in the prevention of this complication.Patients scheduled elective abdominal, thoracic, gynecologic or urologic resection, were randomised to sulphate (600 mg intramuscularly on second day before surgery, then 300 once daily), calcium heparin (5,000 IU subcutaneously t.i.d., starting 2 hours...